CLK-IN-T3 |
Catalog No.GC60716 |
CLK-IN-T3는 CLK1, CLK2 및 CLK3 단백질 키나제에 대해 각각 0.67nM, 15nM 및 110nM의 IC50을 갖는 강력하고 선택적이고 안정적인 CDC 유사 키나제(CLK) 억제제입니다. CLK-IN-T3는 항암 활성이 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2109805-56-1
Sample solution is provided at 25 µL, 10mM.
CLK-IN-T3 is a high potent, selective, and stable CDC-like kinase (CLK) inhibitor with IC50s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity[1].
CLK-IN-T3 inhibits DYRK1A (IC50=260 nM) and DYRK1B (IC50=230 nM)[1]. CLK-IN-T3 (0.1-10.0 µM; 24 hours) results in mild cell cycle arrest at the G2/M boundary with long-duration (24 h)[1]. CLK-IN-T3 (0.5-1.0 µM; 6 hours) decreases phosphorylation of CLK-targeted SR proteins and CLK proteins increase slightly[1]. Cell Cycle Analysis[1] Cell Line: HCT-116 cells
[1]. Funnell T, et al. CLK-dependent exon recognition and conjoined gene formation revealed with a novel smallmolecule inhibitor. Nat Commun. 2017 Feb 23;8(1):7.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *